| 摘要 |
An adjuvant for Fluazifop-butyl, and preferably Fluazifop-P-butyl, having increased activity, lower irritancy and lower toxicity than conventional adjuvants. The adjuvant is C8 to C22 sarcosinate or sarcosinate salt, such as sodium cocoyl sarcosinate, sodium lauroyl sarcosinate, or combinations thereof, which is combined with Fluazifop-P-butyl and provides more effective activity.
|
